Why Is Nuwellis (NASDAQ:NUWE) Down 11.34% Before the Open After Its Post-Split Climb?

Vinay Lochav

04 November 2026 11:32 PM AEDT

Why Is Nuwellis (NASDAQ:NUWE) Down 11.34% Before the Open After Its Post-Split Climb?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Shares fell 11.34% to USD 5.24 in pre-market trading on November 4, 2026, from a USD 5.91 close on November 3.
Second quarter 2026 Revenue was USD 1.97 million, up about 14% from roughly USD 1.7 million a year earlier.
Gross Margin reached 76% in the second quarter, compared with 56% in the prior-year period.
The net loss narrowed to about USD 4.8 million from about USD 12.6 million.
The company reported cash of about USD 3.9 million at June 30, 2026, plus later financing proceeds.

What Moved Nuwellis Before the Open (down USD 0.6702, 11.34%)

Nuwellis (NASDAQ:NUWE) traded 11.34% lower at USD 5.24 in pre-market trading on November 4, 2026, a drop of USD 0.6702 from the Tuesday, November 3, 2026 close of USD 5.91.

No company announcement dated November 3 or November 4, 2026 was located in the research, so the decline is not linked to a confirmed catalyst. A plausible backdrop is profit-taking after a sharp run that followed the reverse stock split.

Recent Company Updates Behind the Volatility

The company disclosed a Reverse Stock Split in a regulatory filing dated October 23, 2026, with split-adjusted trading scheduled to start October 27, 2026. The split ratio was not available in the materials reviewed. On October 27, 2026 the company also announced acceptance of a multicenter pediatric Aquadex study by a pediatric nephrology journal.

Earlier, on October 8, 2026, the company said it would convene a pediatric medical and nursing advisory board on November 18 and 19, 2026. About 12 clinicians from 11 U.S. pediatric centers are expected to evaluate its Vivian pediatric continuous renal replacement therapy system, which remains in development.

Business Background and Latest Results

Nuwellis is a medical technology company whose Aquadex SmartFlow system provides ultrafiltration, a therapy that removes excess fluid from patients with fluid overload, including heart failure.

On September 17, 2026 the company said it had sold 31 Aquadex consoles year to date in 2026, more than its full-year console sales in seven of the previous ten years. It also reported 26% year-over-year U.S. revenue growth in the first half of 2026.

For the quarter ended June 30, 2026, reported on August 13, 2026, revenue was USD 1.97 million, up about 14%, with U.S. revenue up 17%. Operating expenses were about USD 4.7 million. The net loss of about USD 4.8 million included roughly USD 1.7 million of Warrant valuation expense.

Balance Sheet, Financing and Risks

Cash was about USD 3.9 million at June 30, 2026, with no debt. After the quarter ended, the company raised about USD 3.4 million in a registered direct offering and about USD 3.3 million from warrant exercises. The company has said this supports its cash runway into the second quarter of 2027.

The quarterly filing also carried going-concern and Nasdaq listing compliance risk language. Annual operating cash outflow for 2025 was about USD 10.8 million, so continued Capital raising and dilution remain real possibilities for a company of this size.

The shares are volatile and thinly traded.

What to Watch Next

The next scheduled event is the third quarter 2026 report, expected in November 2026, though the company has not confirmed the date in the materials reviewed. Revenue growth, gross margin, console placements and updated cash figures will show whether second quarter trends held.

The pediatric advisory board meeting on November 18 and 19, 2026 is the next milestone for Vivian.

FAQs

Q: Why is the stock lower in pre-market trading on November 4, 2026?

A: It is down 11.34% to USD 5.24, but no company announcement from November 3 or 4, 2026 was identified. The move follows a recent reverse split and a rapid run higher.

Q: What were the latest quarterly results?

A: For the second quarter of 2026, revenue was USD 1.97 million, up about 14%, gross margin was 76% and net loss was about USD 4.8 million.

Q: How much cash does the company have?

A: It reported about USD 3.9 million at June 30, 2026, then raised about USD 3.4 million in a registered direct offering and about USD 3.3 million from warrant exercises afterward.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.